Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects
Cell Biochemistry and Function · 2024
DOI: 10.1002/cbf.70011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Biochemistry and Function, 2024. Verfasst von Chen Lu Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technol…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Immune Checkpoint Inhibitors, Immunoconjugates, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 118 Literaturangaben. Gefördert von: This study was supported by National Natural Science Foundation of China (NO.82174457)..
Abstract (Originalsprache)
Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the family of antibodies that can specifically target two or more different antigens and are a promising option for tumor immunotherapy. Immune checkpoints are antibodies targeting PD‐1, PD‐L1, and CTLA4 and have demonstrated remarkable therapeutic efficacy in the treatment of hematological and solid tumors, whose combination therapies have been shown to synergistically enhance the antitumor effects of BsAbs. In addition, the clinical efficacy of existing monoclonal antibodies targeting PD‐1 (e.g., ipilimumab, nivolumab, pembrolizumab, and cemiplimab) and PD‐L1 (e.g., atezolizumab, avelumab, and durvalumab) could also be enhanced by conjugation to small drugs as antibody−drug conjugates (ADCs). The development of truly effective therapies for patients with treatment‐resistant cancers can be achieved by optimizing the various components of ADCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Förderung
- This study was supported by National Natural Science Foundation of China (NO.82174457).
Zitieren
APA
Li, C. L., Ma, X. Y., & Yi, P. (2024). Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.70011
Vancouver
Li CL, Ma XY, Yi P. Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects. Cell Biochemistry and Function. 2024. doi:10.1002/cbf.70011
BibTeX
@article{Li2024,
author = {Li, Chen Lu and Ma, Xin Yuan and Yi, Ping},
title = {Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects},
journal = {Cell Biochemistry and Function},
year = {2024},
doi = {10.1002/cbf.70011}
}
EUVIMED